| Literature DB >> 31191496 |
Shuqin Zhou1, Yijing Zhuang2, Xiaojuan Zhu3, Fen Yao4, Haiyan Li4, Huifang Li3, Xiaoguang Zou5, Jianhua Wu6, Huifang Zhou7, Gulibaier Nuer3, Yuanchun Huang8, Shao Li9, Qing Peng9.
Abstract
The mechanisms of adaptive resistance of Escherichia coli to aminoglycosides remain unclear. Our RNA-Seq study found that expression of yhjX was markedly upregulated during initial exposure to subinhibitory concentrations of gentamicin. The expression of yhjX was then downregulated dramatically during a second exposure to gentamicin compared to the first exposure. YhjX encodes a putative transporter of the major facilitator superfamily, which is known to be the sole target of the YpdA/YpdB two-component system, the expression of which is highly and specifically induced by pyruvate. To investigate the effect of yhjX on the adaptive resistance of E. coli, in the present study, we constructed yhjX deletion and complemented strains of E. coli ATCC25922. Changes in extracellular pyruvate levels of wide-type and yhjX mutant were measured to determine whether YhjX functions as a pyruvate transporter. The results showed that yhjX deletion improved the growth of E. coli in medium containing subinhibitory concentrations of gentamicin. The yhjX deletion mutant did not exhibit adaptive resistance to subinhibitory concentrations of gentamicin. YhjX might not function as a pyruvate efflux pump in E. coli but was associated with the decrease following a sharp increase in the extracellular pyruvate level. Our findings indicate that yhjX regulates the growth of E. coli in the presence of a subinhibitory concentration of gentamicin and mediates the adaptive resistance to gentamicin.Entities:
Keywords: Escherichia coli; YjhX; adaptive resistance; bacterial growth; gentamicin
Year: 2019 PMID: 31191496 PMCID: PMC6545925 DOI: 10.3389/fmicb.2019.01180
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Primers used for qRT-PCR.
| Gene | Forward primer | Reverse primer | References |
|---|---|---|---|
| ATGTATGTGATTGGTGTAGCGAAAG | CAGAAAGGTTGGCGATGGA | ||
| CATTACCGGGATGCTGCAAA | GGTCATTTTCTCGTGCGCTT | ||
| GGACGATCTGTGGGCTGAA | GACATCACCACCGCCAAA | ||
| GGCATCCGGGTGAAGAACTT | AACTTATGCCGTCGAACATATGG | ||
| AACTTATGCCGTCGAACATATGG | TGTTTTCCAGCTCCATAGCC | ||
| ACGTACCGGCTGACGACTAC | CTTATCGATTTCGCCACGTT | ||
| AGATTTTGGCGGAGCGTTT | ATTTATCATGTGGGGCATCCT’ | ||
| CGGTCAACACCTGCCACAT | TGGATTGGTTTCTTCGCCTCT | ||
| ACTTACGAGCAGATCAAAGC | AGTTTCACGAAGTTGTCGTT |
FIGURE 1Growth curves of the E. coli ATCC 25922 wild-type, ΔyhjX mutant and complemented strains in the presence of subinhibitory concentrations of gentamicin. (A) Control-WT: growth curve of E. coli ATCC25922 wild-type (without pretreatment) in MHB with ½ MIC gentamicin; pretreated-WT: growth curve of E. coli ATCC25922 wild-type (pretreated with ½ MIC gentamicin) in MHB with ½ MIC gentamicin. (B) Control-KO: growth curve of the ΔyhjX knock-out strain (without pretreatment) in MHB with ½ MIC gentamicin; pretreated-KO: growth curve of the ΔyhjX knock-out strain (pretreated with ½ MIC gentamicin) in MHB containing ½ MIC gentamicin. (C) Control-C: growth curve of the ΔyhjX complemented strain (without pretreatment) in MHB with ½ MIC gentamicin; pretreated-C: growth curve of the ΔyhjX complemented strain (pretreated with ½ MIC gentamicin) in MHB containing ½ MIC gentamicin.
Validation of RNA-Seq results using qRT-PCR.
| Gene | Description | RNA-Seq | qRT- PCR |
|---|---|---|---|
| Fold change | |||
| Membrane protein | 20.65 | 46.57 | |
| Flagellar motor switch protein | 2.18 | 5.04 | |
| Inhibitor of the cpx response periplasmic adaptor protein | 11.26 | 23.74 | |
| Type II citrate synthase | 0.32 | 0.24 | |
| Pyruvate dehydrogenase | 0.49 | 0.34 | |
| Succinate dehydrogenase cytochrome b556 small membrane subunit | 0.43 | 0.31 | |
| Succinate dehydrogenase cytochrome b556 small membrane subunit | 0.47 | 0.25 | |
| Regulator of yhjX | 0.75 | 0.89 | |
FIGURE 2Number of genes (classified by functional category) upregulated and downregulated in response to sub-MIC gentamicin in the RNA-Seq data. MT, membrane and transporter; TCA, TCA cycle; GG, glycolysis/gluconeogenesis. VIR, virulence; MOT, motility; ORP, oxidation–reduction process; RT, ribosome and translation; HP, hypothetical protein; DBR, DNA binding and recombination; STR, stress response; BSM, biosynthesis of secondary metabolites; ECA, electron carrier activity; CAM, other carbohydrate metabolism processes; PHO, phosphorylation; TRA, transcription; LPB, lipid biosynthesis; PAM, protein and amino acid metabolism; BAA, biosynthesis of amino acids; CH, cell shape; NAM, nucleic acid metabolism; DR, DNA replication; MM, methane metabolism; NM, nitrogen metabolism; GDM, glyoxylate and dicarboxylate metabolism; MIB, metal ion binding; CM, carnitine metabolic process; AAM, ascorbate and aldarate metabolism; LIA, lysozyme inhibitor activity.
FIGURE 3Changes in gene expression of yhjX and ypdB in E. coli ATCC25922 wild-type after initial exposure and re-exposure to ½ MIC gentamicin. ∗∗ indicates a statistically significant difference (P < 0.01) compared to the control (without treatment); # indicates a statistically significant difference (P < 0.01) compared to initial exposure to gentamicin.
FIGURE 4Growth curves of the E. coli wild-type, ΔyhjX mutant and complemented strains in the presence or absence of ½ MIC gentamicin. WT-1/2MIC, growth curve of E. coli ATCC25922 wild-type in MHB containing ½ MIC gentamicin; WT-no drug, growth curve of E. coli ATCC25922 wild-type in MHB with no drug; KO-1/2MIC, growth curve of the E. coli ATCC25922 ΔyhjX mutant in MHB containing ½ MIC gentamicin; KO-no drug, growth curve of the E. coli ATCC25922 ΔyhjX mutant in MHB with no drug; C-1/2MIC, growth curve of the E. coli ATCC25922 ΔyhjX complemented strain in MHB containing ½ MIC gentamicin; C-no drug, growth curve of the E. coli ATCC25922 ΔyhjX complemented strain in MHB with no drug.
FIGURE 5Comparison of relative expression of yhjX and extracellular pyruvate measurement in different media. (A) Relative expression of yhjX in E. coli ATCC 25922 wild-type in different media, including MHB, MH medium with ½ MIC gentamicin, M9 minimal medium containing 0.4% glucuronate and M9 minimal medium with 0.4% glucose. (B) ATCC 25922 wild-type (WT) and ΔyhjX knock-out mutant (KO) were inoculated in MHB with and without ½ MIC gentamicin, M9 containing 0.4% glucuronate and M9 containing 0.4% glucose. Concentrations of extracellular pyruvate in different cultures were determined before inoculation, 30 min after inoculation and 60 min after inoculation.